TY - JOUR
T1 - Investigational drugs in HIV
T2 - Pros and cons of entry and fusion inhibitors (Review)
AU - Rullo, Emmanuele Venanzi
AU - Ceccarelli, Manuela
AU - Condorelli, Fabrizio
AU - Facciolà, Alessio
AU - Visalli, Giuseppa
AU - D'Aleo, Francesco
AU - Paolucci, Ivana
AU - Cacopardo, Bruno
AU - Pinzone, Marilia Rita
AU - Rosa, Michele D.I.
AU - Nunnari, Giuseppe
AU - Pellicanò, Giovanni F.
N1 - Publisher Copyright:
© 2019 Spandidos Publications. All rights reserved.
PY - 2019
Y1 - 2019
N2 - Despite the profound changes and improvements reached in the field of HIV treatment, tolerability and adherence to highly active antiretroviral therapy remains a challenge. Furthermore, multi-experienced patients could take advantage of drugs with different mechanisms of action to combat the spread of resistance to actual therapy. For these reasons identification of new HIV drugs is crucial. Among all the molecules that at present are under investigation, entry and fusion inhibitors pose an interesting class owing to their peculiar characteristics, including prevention of entry of the virus into the human cells. In this study, we reviewed articles, clinical trials, and conference communications about all the drugs under investigation belonging to the class of entry and fusion inhibitors that are at least in phase I clinical trials.
AB - Despite the profound changes and improvements reached in the field of HIV treatment, tolerability and adherence to highly active antiretroviral therapy remains a challenge. Furthermore, multi-experienced patients could take advantage of drugs with different mechanisms of action to combat the spread of resistance to actual therapy. For these reasons identification of new HIV drugs is crucial. Among all the molecules that at present are under investigation, entry and fusion inhibitors pose an interesting class owing to their peculiar characteristics, including prevention of entry of the virus into the human cells. In this study, we reviewed articles, clinical trials, and conference communications about all the drugs under investigation belonging to the class of entry and fusion inhibitors that are at least in phase I clinical trials.
KW - Anti-HIV agents
KW - Antiviral drug resistance
KW - HAART
KW - HIV fusion inhibitors
KW - Safety
UR - http://www.scopus.com/inward/record.url?scp=85060580582&partnerID=8YFLogxK
U2 - 10.3892/mmr.2019.9840
DO - 10.3892/mmr.2019.9840
M3 - Review article
SN - 1791-2997
VL - 19
SP - 1987
EP - 1995
JO - Molecular Medicine Reports
JF - Molecular Medicine Reports
IS - 3
ER -